The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Effect of daratumumab on MRD measured by NGF in myeloma
Alessandro Gozzetti, MD, PhD, Azienda Ospedaliera Universitaria Senese, Siena, Italy, discusses the 18-month follow up of the DART4MM study (NCT03992170) evaluating daratumumab efficacy in multiple myeloma patients who achieved a very good partial response (VGPR)/complete response (CR) but remained measurable residual disease (MRD) positive by next-generation flow (NGF) after initial therapy. NGF is a novel high sensitivity approach for myeloma MRD evaluation. Two 8-colour tubes allow the evaluation of all markers needed to differentiate normal from malignant plasma cells (PCs). Long term follow-up investigating the maintenance of MRD negativity will continue. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
